시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 B형 간염 바이러스(HBV) 시장 보고서(2025년)
Hepatitis B Virus (HBV) Global Market Report 2025
상품코드 : 1691856
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,342,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,167,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,992,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 B형 간염 바이러스(HBV) 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 CAGR 9.8%, 107억 2,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의료의 상승, 환자 옹호 단체의 지지 증가, 예방 접종 프로그램 증가, 건강 관리 지출 증가로 인한 것입니다. 예측 기간의 주요 동향으로는 신약 개발, 진단 기술 진보, 관민 파트너십, 혁신적인 생물학적 요법 등이 있습니다.

B형 간염 감염의 높은 유병률은 향후 수년간 B형 간염 바이러스 시장의 성장을 가속할 것으로 예상됩니다. B형 간염은 B형 간염 바이러스(HBV)에 의해 유발되는 간 감염이며, 예방접종으로 예방할 수 있습니다. B형 간염 감염률 증가는 진단 검사 및 치료 옵션 수요를 높일 가능성이 높습니다. 예를 들어 2024년 4월 스위스에 본부를 두고 있는 정부간 기관인 세계보건기구(WHO)는 2022년에는 2억 5,400만명이 만성 B형 간염을 앓고 있으며 매년 120만명이 새롭게 B형 간염을 앓고 있다고 보고했습니다. 그 결과, B형 간염 감염의 높은 유병률은 B형 간염 바이러스 시장에 큰 영향을 미칠 것으로 예상됩니다.

간 질환이나 간경변을 경험하는 환자 수 증가가 향후 B형 간염 바이러스 시장의 성장을 가속할 것으로 예상됩니다. B형 간염 바이러스는 이 질병과 관련된 증상과 부작용을 완화하면서 신장 기능에 영향을 줄 수 있습니다. 예를 들어 2023년 7월 영국 정부 부문 Office for Health Improvement and Disparities는 2022년 회계연도 중 잉글랜드에서는 간질환에 의한 입원이 82,290건 기록되어 인구 10만명당 150.6건의 비율에 상당한다고 보고했습니다. 이는 2021년에 종료된 전 회계년도의 입원 환자 수 67,458명에서 증가한 것을 의미하며, 국민들 사이에서 간 건강에 대한 우려가 높아지고 있는 것을 부각하고 있습니다. 그러므로, 환자의 간장애나 간경변의 발생률이 상승하고 있는 것이, B형 간염 바이러스 시장의 성장에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

JHS
영문 목차

영문목차

Hepatitis B virus (HBV) is a liver-targeting viral infection transmitted through contact with infected blood or bodily fluids, including vertical transmission from mother to child during childbirth. The primary approach to managing HBV involves the use of antiviral medications to suppress viral replication, while vaccination plays a crucial role in prevention.

Hepatitis B virus (HBV) is categorized into acute and chronic forms. Acute hepatitis B is a short-term infection resulting from HBV, typically occurring within the first six months of exposure. The medications for acute cases aim to clear the virus from the body and prevent chronic infection. Treatment options include immune modulator drugs, antiviral medications, vaccines, and, in some cases, surgery. These treatments are administered to individuals across various age groups, including pediatrics, adults, and seniors, with medical providers, patients, and healthcare payers being involved in the healthcare process.

The hepatitis B virus (HBV) market research report is one of a series of new reports from The Business Research Company that provides hepatitis B virus (HBV) market statistics, including hepatitis B virus (HBV) industry global market size, regional shares, competitors with a hepatitis B virus (HBV) market share, detailed hepatitis B virus (HBV) market segments, market trends and opportunities and any further data you may need to thrive in the hepatitis B virus (HBV) industry. This hepatitis B virus (HBV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis B virus (HBV) market size has grown strongly in recent years. It will grow from $6.71 billion in 2024 to $7.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of hepatitis b virus (hbv), growing demand for hbv diagnostics, expanding hbv vaccine coverage, rising awareness of hepatitis b virus (hbv).

The hepatitis B virus (HBV) market size is expected to see strong growth in the next few years. It will grow to $10.72 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to the rise of personalized medicine, growing support from patient advocacy groups, rising vaccination programs, increase in healthcare expenditure. Major trends in the forecast period include development of new drugs, advancements in diagnostic technologies, public-private partnerships, innovative biological therapies.

The high prevalence of hepatitis B infections is anticipated to drive the growth of the hepatitis B virus market in the coming years. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), which can be prevented through vaccination. Increasing rates of hepatitis B infections are likely to elevate the demand for diagnostic tests and treatment options. For instance, in April 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that in 2022, 254 million people were living with chronic hepatitis B, with 1.2 million new cases diagnosed each year. Consequently, the high prevalence of hepatitis B infections is expected to significantly influence the hepatitis B virus market.

An increase in the number of patients experiencing liver damage or cirrhosis is expected to drive the growth of the hepatitis B virus market in the future. Cirrhosis is a serious liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue. The hepatitis B virus can impact kidney function while alleviating symptoms and side effects associated with the condition. For example, in July 2023, the Office for Health Improvement and Disparities, a UK government department, reported that in the financial year ending 2022, England recorded 82,290 hospital admissions due to liver disease, equating to a rate of 150.6 per 100,000 people. This marks an increase from 67,458 admissions in the previous financial year ending in 2021, highlighting a growing concern about liver health within the population. Therefore, the rising incidence of liver damage or cirrhosis among patients is contributing to the growth of the hepatitis B virus market.

Prominent companies operating within the hepatitis B virus (HBV) market are placing a strong emphasis on the advancement of cutting-edge diagnostics and treatment options. One such innovation involves the utilization of highly sensitive chemiluminescent microparticle immunoassay (CMIA) technology to gain a competitive edge in the market. A case in point is Abbott Laboratories, a healthcare company based in the United States, which, in May 2022, introduced the HBsAg Next Qualitative Solution Test. This test is designed to facilitate the early detection of the Hepatitis B virus (HBV) in human serum and plasma samples. By enhancing early detection capabilities, this advanced chemiluminescent microparticle immunoassay (CMIA) not only contributes to improved patient outcomes but also safeguards the integrity of blood supplies. It enables both early detection of HBV in human serum and plasma (blood) samples and population screening, all thanks to its highly sensitive technology.

In July 2023, Brii Biosciences Ltd., a biotechnology firm headquartered in China, secured licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc., an American biotechnology company. This transaction, for an undisclosed sum, grants Brii Biosciences Ltd. access to valuable insights related to both the prevention and treatment of hepatitis B. VBI Vaccines Inc. specializes in the development of a vaccine designed to prevent infections caused by the hepatitis B virus.

Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.

North America was the largest region in the hepatitis B Virus (HBV) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis B virus (HBV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis B Virus (HBV) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis b virus (hbv) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hepatitis b virus (hbv) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis b virus (hbv) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Hepatitis B Virus (HBV) Market Characteristics

3. Hepatitis B Virus (HBV) Market Trends And Strategies

4. Hepatitis B Virus (HBV) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hepatitis B Virus (HBV) Growth Analysis And Strategic Analysis Framework

6. Hepatitis B Virus (HBV) Market Segmentation

7. Hepatitis B Virus (HBV) Market Regional And Country Analysis

8. Asia-Pacific Hepatitis B Virus (HBV) Market

9. China Hepatitis B Virus (HBV) Market

10. India Hepatitis B Virus (HBV) Market

11. Japan Hepatitis B Virus (HBV) Market

12. Australia Hepatitis B Virus (HBV) Market

13. Indonesia Hepatitis B Virus (HBV) Market

14. South Korea Hepatitis B Virus (HBV) Market

15. Western Europe Hepatitis B Virus (HBV) Market

16. UK Hepatitis B Virus (HBV) Market

17. Germany Hepatitis B Virus (HBV) Market

18. France Hepatitis B Virus (HBV) Market

19. Italy Hepatitis B Virus (HBV) Market

20. Spain Hepatitis B Virus (HBV) Market

21. Eastern Europe Hepatitis B Virus (HBV) Market

22. Russia Hepatitis B Virus (HBV) Market

23. North America Hepatitis B Virus (HBV) Market

24. USA Hepatitis B Virus (HBV) Market

25. Canada Hepatitis B Virus (HBV) Market

26. South America Hepatitis B Virus (HBV) Market

27. Brazil Hepatitis B Virus (HBV) Market

28. Middle East Hepatitis B Virus (HBV) Market

29. Africa Hepatitis B Virus (HBV) Market

30. Hepatitis B Virus (HBV) Market Competitive Landscape And Company Profiles

31. Hepatitis B Virus (HBV) Market Other Major And Innovative Companies

32. Global Hepatitis B Virus (HBV) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis B Virus (HBV) Market

34. Recent Developments In The Hepatitis B Virus (HBV) Market

35. Hepatitis B Virus (HBV) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기